News
FGEN
1.150
-1.71%
-0.020
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
NASDAQ · 18h ago
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
NASDAQ · 1d ago
KIND PHARMACEUTICALS-RESOLUTION OF DISPUTE WITH FIBROGEN WAS REGARDING CO'S HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR TECHNOLOGY
Reuters · 3d ago
KIND PHARMACEUTICALS-HANGZHOU ANDAO PHARMACEUTICAL, CO ANNOUNCED A RESOLUTION OF THEIR RECENT DISPUTE WITH FIBROGEN
Reuters · 3d ago
KIND PHARMACEUTICALS-PARTIES AGREED TO WITHDRAW ALL PENDING LEGAL PROCEEDINGS BETWEEN THEM REGARDING HIF-PHI TECHNOLOGY,WITHOUT PAYMENT BY EITHER PARTY
Reuters · 3d ago
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
NASDAQ · 3d ago
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
NASDAQ · 3d ago
Weekly Report: what happened at FGEN last week (0408-0412)?
Weekly Report · 5d ago
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
NASDAQ · 04/12 14:23
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
NASDAQ · 04/12 14:00
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
NASDAQ · 04/09 13:29
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
NASDAQ · 04/08 16:13
Weekly Report: what happened at FGEN last week (0401-0405)?
Weekly Report · 04/08 09:08
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
NASDAQ · 04/06 10:37
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
NASDAQ · 04/05 16:58
FibroGen falls after early-stage data for prostate cancer drug
FibroGen falls after early-stage data for prostate cancer drug. The company announced initial results from a Phase 1 study for its prostate cancer therapy, FG-3246. The drug led to a median progression-free survival of 8.7 months, FibroGen says.
Seeking Alpha · 04/03 19:54
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday. The company reportedly issued a weak outlook at the J.P. Morgan Retail Roundup investor conference. ARCA biopharma, Inc. Shares climbed 108% in the mid-day session.
Benzinga · 04/03 17:56
12 Health Care Stocks Moving In Wednesday's Intraday Session
ARCA biopharma (NASDAQ:ABIO) shares moved upwards by 84.8% to $3.16 during Wednesday's regular session. Vanda Pharma shares rose by 39.38% and Kintara Therapeutics stock rose by 71.81% in the same session. The company's Q4 earnings report came out yesterday.
Benzinga · 04/03 16:31
FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape
FibroGen Inc announced topline data from the Phase 1 study of FG-3246 in prostate cancer. The drug is a potential first-in-class anti-CD46 antibody drug conjugate with an MMAE-containing payload. In the efficacy analysis, prostate-specific antigens reductions of over 50% were observed in 36% of patients.
Benzinga · 04/03 14:02
FibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare movers
Healthcare On the Move: FibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare movers. S&P 500 Health Care Sector +0.26% to 1685.56. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 04/03 14:00
More
Webull provides a variety of real-time FGEN stock news. You can receive the latest news about Fibrogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About FGEN
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.